ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  05/24 04:00:00 pm EDT
45.80 USD   -4.46%
05/24Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Keeps Neutral Rating
MT
05/19Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reiterates Overweight Rating
MT
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx Pharmaceutical : Says Crysvita Wins Canada Approval for Second Indication for Endocrine Disorder

09/07/2021 | 09:58am EDT


© MT Newswires 2021
All news about ULTRAGENYX PHARMACEUTICAL INC.
05/24Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Kee..
MT
05/19Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reit..
MT
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
GL
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
AQ
05/19Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two ..
CI
05/17Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Ther..
MT
05/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
AQ
05/10TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Co..
CI
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 373 M - -
Net income 2022 -512 M - -
Net cash 2022 437 M - -
P/E ratio 2022 -6,29x
Yield 2022 -
Capitalization 3 203 M 3 203 M -
EV / Sales 2022 7,41x
EV / Sales 2023 5,81x
Nbr of Employees 1 119
Free-Float 95,6%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 45,80 $
Average target price 125,44 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-45.53%3 352
GILEAD SCIENCES, INC.-11.38%79 850
REGENERON PHARMACEUTICALS, INC.8.63%73 473
VERTEX PHARMACEUTICALS22.26%68 632
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666